Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 11:24 AM ET
JAZZ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.16B
- P/E (TTM)
- 14.95
- Forward P/E
- 8.41
- EPS (TTM)
- $14.59
- Dividend yield
- None
- 52-week range
- 128.80 – 266.38
- Day range
- 217.36 – 229.16
- Volume / Avg
- 453.12K / 850.55K
- Beta
- —
- Shares outstanding
- 64.91M
- Next earnings
- Nov 4, 2026
52-week range
JAZZ stock today
Shares of Jazz Pharmaceuticals (JAZZ) are trading lower on Oct 8 at $218.08, a drop of 5.67% or $13.11 per share, versus the S&P 500's 0.40% decline. Shares are 18.1% below their 52-week high of $266.38, set on Aug 25, 2026 and 69.3% above the 52-week low of $128.80, in the middle of the past year's range. JAZZ is up 36.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 68.4%.
At 14.9x trailing earnings, Jazz Pharmaceuticals trades below the peer-group median of 146.6x. Its forward P/E of 8.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Jazz Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Jazz Pharmaceuticals
Company profileJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Renee D. Gala
- Headquarters
- Dublin
- Employees
- 2,890
- IPO year
- 2007
- Website
- jazzpharma.com
Financial highlights
Full financialsIn fiscal 2025, Jazz Pharmaceuticals generated $4.27 billion in revenue, up 4.9% from fiscal 2024, its 16th consecutive year of revenue growth. Jazz Pharmaceuticals reported a net loss of $356.1 million, compared with net income of $560.1 million a year earlier. Operating margin was -10.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B |
| Growth | +4.88% | +6.12% | +4.78% | +18.26% | +30.91% |
| Net income | $-356.15M | $560.12M | $414.83M | $-224.06M | $-329.67M |
| EPS (diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$294.50+35.04%
- Strong buy 7
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $5.65
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $2.78 vs —
JAZZ news
All JAZZ newsJazz Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ASNDAscendis Pharma A/S | 223.35 | -2.22% | $14.70B | vs JAZZ |
| SMMTSummit Therapeutics Inc. | 17.03 | -5.15% | $13.58B | vs JAZZ |
| BBIOBridgeBio Pharma Inc. | 64.86 | -2.47% | $12.68B | vs JAZZ |
| CORTCorcept Therapeutics Incorporated | 116.46 | -2.63% | $12.59B | vs JAZZ |
| ELANElanco Animal Health Incorporated | 22.24 | -0.54% | $11.11B | vs JAZZ |
| MDGLMadrigal Pharmaceuticals Inc. | 475.49 | -2.51% | $10.99B | vs JAZZ |
| BMRNBioMarin Pharmaceutical Inc. | 54.26 | -1.70% | $10.50B | vs JAZZ |
| VTRSViatris Inc. | 17.17 | -1.83% | $19.72B | vs JAZZ |
Indexes, lists and sector
Jazz Pharmaceuticals stock FAQ
What is Jazz Pharmaceuticals's stock price today?
JAZZ last traded at $218.08 as of Oct 8, 11:24 AM EDT, down 5.67% on the day. Prices are delayed at least 15 minutes.
When is Jazz Pharmaceuticals's next earnings date?
Jazz Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $5.65.
What is JAZZ's P/E ratio?
JAZZ trades at a trailing P/E ratio of 14.95 and a forward P/E of 8.41, compared with a median of 146.6 for its closest peers.
Who is Jazz Pharmaceuticals's CEO?
Ms. Renee D. Gala is the chief executive officer of Jazz Pharmaceuticals plc, which has about 2,890 employees.
What is the JAZZ 52-week high?
The 52-week high for JAZZ is $266.38 and the 52-week low is $128.80. The stock is currently 18.1% below its high.